Table 1.
Clinicopathological characteristics of all patients
| Unique ID | Age (year) | Gender | Nephrectomy type | Creatinine | Primary tumor status | Tumor size (mm) | Fuhrmann grade | Leibovich score 2003a | Leibovich score 2018b | Time to metastasis (days) | Pair ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rcc9 | 51 | Female | Radical | 58 | T1a | 38 | 3 | 2 | 5 | 1544 | 1 |
| Rcc8 | 63 | Male | Radical | 60 | T1a | 40 | 3 | 1 | 3 | 1994 | 2 |
| Rcc3 | 66 | Male | Radical | 113 | T1a | 35 | 3 | 1 | 3 | 2632 | 3 |
| Rcc11 | 66 | Male | Partial | 61 | T1a | 15 | 3 | 2 | 5 | 965 | 4 |
| Rcc1 | 72 | Female | Radical | 106 | T1a | 20 | 2 | 0 | 2 | 2680 | 5 |
| Rcc2 | 72 | Male | Radical | 109 | T1b | 50 | 2 | 2 | 5 | 2319 | 6 |
| Rcc5 | 83 | Male | Radical | 81 | T1b | 50 | 2 | 2 | 5 | 109 | 7 |
| Rcc6 | 67 | Male | Radical | 176 | T1b | 48 | 2 | 2 | 5 | 1385 | 8 |
| Rcc13 | 34 | Male | Partial | 73 | T1a | 23 | 3 | 1 | 3 | 1 | |
| Rcc24 | 47 | Female | Partial | 48 | T1a | 40 | 3 | 1 | 3 | 1 | |
| Rcc17 | 54 | Male | Partial | 68 | T1a | 35 | 3 | 1 | 3 | 2 | |
| Rcc20 | 66 | Male | Radical | 67 | T1a | 30 | 3 | 1 | 3 | 2 | |
| Rcc21 | 57 | Male | Partial | 73 | T1a | 30 | 3 | 1 | 3 | 3 | |
| Rcc16 | 62 | Male | Radical | 82 | T1a | 30 | 3 | 1 | 3 | 3 | |
| Rcc23 | 74 | Male | Partial | 81 | T1a | 16 | 3 | 1 | 3 | 4 | |
| Rcc22 | 66 | Male | Partial | 83 | T1a | 38 | 3 | 1 | 3 | 4 | |
| Rcc10 | 78 | Female | Partial | 64 | T1a | 20 | 2 | 0 | 2 | 5 | |
| Rcc18 | 68 | Female | Partial | 45 | T1a | 20 | 2 | 0 | 2 | 5 | |
| Rcc14 | 72 | Male | Partial | 97 | T1b | 55 | 2 | 2 | 5 | 6 | |
| Rcc4 | 63 | Male | Radical | 82 | T1b | 50 | 2 | 2 | 5 | 6 | |
| Rcc7 | 76 | Male | Radical | 98 | T1b | 45 | 2 | 2 | 5 | 7 | |
| Rcc15 | 75 | Male | Radical | 73 | T1b | 45 | 2 | 2 | 5 | 7 | |
| Rcc12 | 63 | Male | Radical | 80 | T1b | 45 | 2 | 2 | 5 | 8 | |
| Rcc19 | 68 | Male | Radical | 68 | T1b | 45 | 2 | 2 | 5 | 8 |
Clinicopathological characteristics of progressor (n = 8) and nonprogressor (n = 16) patients. Nonprogressors were matched 2:1 to progressors for sex, age, primary tumor stage and size, Fuhrman grade, and eGFR. Pair-ID refers to matched nonprogressors and progressors. No patients exhibited tumor thrombus, sarcomatoid differentiation, or constitutional symptoms. Patients with distant metastases that were not treatment naïve, had lymph node metastasis, suffered from heart failure (grade ≥ 3 according to the New York Heart Association Classification), or used immunosuppressive drugs due to transplantation or severe rheumatic disease at the time of the biopsy were excluded from the study
aScoring was performed according to the 2003
bScoring was performed according to the 2018 Score